Intestinal vasculitis in Adamantiades‐Behçet disease presenting as acute abdomen

Hoxha, FT; Hashani, S.; Krasniqi, Aresa; Pllana, M; D, Komoni; Pustina, Belinda; Sopa, Ramadan; Cc, Zouboulis

doi:10.1111/j.1468-3083.2009.03257.x

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monoarthritis was the only symptom during the first 3 years: joint involvement represents the initial manifestation in about 7% of patients with ABD [42] and has proved to be associated with delayed diagnosis in the absence of other suggestive symptoms [43] . This case bears an epidemiological interest, as this is the fourth ever reported patient with ABD originating from Kosovo [44] . The lack of reported cases is even more surprising if we consider the neighbourhood of Kosovo and Albania with countries with a high prevalence, namely Greece, Turkey, Italy and Serbia.…”

Section: Case Reportmentioning

confidence: 99%

Infliximab for the Treatment of Refractory Adamantiades-Behçet Disease with Articular, Intestinal, Cerebral and Ocular Involvement

Donghi¹,

Mainetti²

2010

Dermatology

View full text Add to dashboard Cite

Section: Case Reportmentioning

confidence: 99%

Infliximab for the Treatment of Refractory Adamantiades-Behçet Disease with Articular, Intestinal, Cerebral and Ocular Involvement

Donghi¹,

Mainetti²

2010

Dermatology

View full text Add to dashboard Cite

“…A report showed that 40% of adult intestinal Behcet's disease patients did not respond to corticosteroid treatment [ 4 ]. Intractable cases occasionally failed in intestinal perforations and gastrointestinal surgery may cause severe, extended pathergy phenomenon with lethal outcome [ 9 ]. The prolonged use of corticosteroids in pediatric patients is associated with growth disorders, abnormal bone metabolism, and mental disorders.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet’s Disease

Kaji

Kishi

Miyamae

et al. 2015

Case Reports in Rheumatology

View full text Add to dashboard Cite

We describe our experience with a juvenile patient who had refractory intestinal Behcet's disease that responded to adalimumab, a fully humanized antibody against soluble TNF-α and its receptor. The patient, a 13-year-old girl, presented with oral aphthous ulcers, vulvar pain, and rashes on the lower extremities. She gradually developed a low-grade fever, abdominal pain, diarrhea, and hematochezia. Lower gastrointestinal endoscopy revealed ulcers in the terminal ileum, consistent with intestinal Behcet's disease. Methylprednisolone pulse therapy was initiated, after which the symptoms transiently improved, but, during the corticosteroid taper, the abdominal pain recurred. The symptoms resolved soon after the administration of adalimumab. Of importance, the dose of corticosteroids was successfully reduced without exacerbation during 8 months of observation. This is the first reported case in which adalimumab was used for pediatric gastrointestinal Behcet's disease. Adalimumab is a good choice for intestinal Behcet's disease refractory to conventional treatment.

show abstract

“…Systemic prednisolone should therefore be administered prior to any surgical or otherwise invasive procedure deemed inevitable [6]. In our patient, 20-day vacuum pump therapy under oral prednisolone led to marked wound granulation.…”

mentioning

confidence: 94%